Contrast‑enhanced magnetic resonance imaging with a novel nano‑size contrast agent for the clinical diagnosis of patients with lung cancer

Abstract

Abstract. Recent studies have indicated that magnetic resonance imaging (MRI) efficiently diagnoses lung cancer. However, the efficacy of MRI in diagnosing lung cancer requires improving for patients in the early stage of the disease. In the present study, a novel nano-sized contrast agent of chistosan/Fe 3 O 4 -enclosed bispecific antibodies (BsAbCENS) was introduced, which targeted carcino-embryonic antigen (CEA) and neuron-specific enolase (NSE) in lung cancer cells. The diagnostic efficacy of contrast-enhanced MRI with BsAbCENS (CEMRI-BsAbCENS) was investigated in a total of 182 patients with suspected lung cancer who had high serum levels of CEA and NSE. BsAbCENS was administered by pulmonary inhalation prior to the MRI scan. The results revealed that CEA and NSE were overexpressed in human lung cancer cell lines. BsAbCENS bound with CEA and NSE on the surface of human lung cancer cells and produced a higher signal intensity than MRI alone for the diagnosis of patients with lung cancer. The diagnostic data revealed that CEMRI-BsAbCENS diagnosed 124/182 lung cancer cases, whereas CEMRI only diagnosed 98/182, which was significantly less (P<0.01). In addition, the survival rate of patients with lung cancer diagnosed by CEMRI-BsAbCENS was significantly higher than the mean 5-year survival rate (P<0.01). Furthermore, the pharmacodynamics demonstrated that BsAbCENS was metabolized within 24 h. The results of the present study indicate that the efficacy and accuracy of lung cancer diagnosis are improved by CEMRI-BsAbCENS. In conclusion, these results provide a potential novel protocol for the diagnosis of tumors in patients with suspected early stage lung cancer.

Role of Gd2O3‑doped carbon‑11‑choline‑lenvatinib nanoparticles contrast agent PET/CT in the diagnosis of patients with lung cancer

“…Contrast agent may increase the sensitivity and accuracy of CT imaging for the diagnosis of early stage NSCLC (23). A novel nano-sized chistosan/Fe 3 O 4 -enclosed bispecific antibody had been identified as an efficient contrast agent in lung cancer diagnosis (40). However, a previous study reported that a nonionic intravenous contrast agent did not cause clinically significant improvement to 18F-FDG PET/CT in patients with lung cancer (41).…”

Pulmonary inhalation for disease treatment: Basic research and clinical translations

“…Drug delivery by pulmonary inhalation can be used to treat and diagnose lung diseases; it is a safe, convenient, and non-invasive diagnostic modality. GAO et al [ 340 ] described a novel nano-inhaled contrast agent that can produce a higher signal intensity than MRI alone in diagnosing lung cancer, improving the validity and accuracy of a lung cancer diagnosis. With the application of inorganic NPs as lung delivery carriers, materials based on inorganic plasmonic and magnetic properties can be used to diagnose diseases of the respiratory system, and external magnetic fields, such as positron emission tomography, magnetic resonance imaging, and computed tomography, can direct these magnetic NPs to target sites [ 341 ].…”

Intratracheal Delivery of Nano- and Microparticles and Hyperpolarized Gases

“…42 SPIONs (about 130 nm) have been nebulized and delivered to rat lungs, enabling lung imaging with high sensitivity and efficacy via magnetic particle imaging (Fig 4B). 43 Novel nanosized MRI contrast agents developed by Gao et al, 44 chitosan/Fe 3 O 4enclosed bispecific antibodies, were shown to significantly enhance signal intensity for lung cancer after pulmonary inhalation, when compared with MRI alone.…”